N2Generate

The Dementia UK Ecosystem (DUKE) brings together leaders from the UK DRI, Dementias Platform UK, the National Institute for Health Research, the pharmaceutical industry, and funders to create a cohesive community, coordinating efforts to accelerate progress in tackling dementia.

Prof Sir David Klenerman, UK DRI Group Leader at Cambridge, and Prof Sir Shankar Balasubramanian have been awarded the 2022 Breakthrough Prize for their development of Next Generation Sequencing. The groundbreaking technology significantly reduced the time and cost associated with sequencing a human genome, revolutionising modern research and medicine.

We have a clearly defined vision at the UK DRI to develop effective therapeutics, diagnostics and technologies for people living with dementia. Alongside building our disease knowledge over the coming years, we will also make progress in translating these discoveries into the clinic.

Our efforts to increase the diversity of our team, ensure inclusion and promote equality of opportunity, align with our vision for the UK DRI’s Institute culture and identity as a world-leader in dementia research.